TY  - JOUR
PB  - NATURE PORTFOLIO
JF  - npj Parkinson's Disease
VL  - 8
TI  - Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease
N1  - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article?s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article?s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
ID  - discovery10162570
UR  - https://doi.org/10.1038/s41531-022-00384-x
Y1  - 2022/11/12/
AV  - public
EP  - 7
SN  - 2373-8057
A1  - Batzu, Lucia
A1  - Rota, Silvia
A1  - Hye, Abdul
A1  - Heslegrave, Amanda
A1  - Trivedi, Dhaval
A1  - Gibson, Lucy L
A1  - Farrell, Chloe
A1  - Zinzalias, Pavlos
A1  - Rizos, Alexandra
A1  - Zetterberg, Henrik
A1  - Chaudhuri, K Ray
A1  - Aarsland, Dag
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Neurosciences
KW  -  Neurosciences & Neurology
KW  -  NONMOTOR SYMPTOMS SCALE
KW  -  ALZHEIMERS-DISEASE
KW  -  TAU
KW  -  BIOMARKER
KW  -  IMPAIRMENT
KW  -  PREDICTION
KW  -  DIAGNOSIS
KW  -  ACCURACY
KW  -  DEMENTIA
KW  -  DECLINE
N2  - Early identification of cognitive impairment in Parkinson?s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in PD. Baseline concentrations of plasma p-tau181 and NfL were measured in a cohort of 136 patients with PD and 63 healthy controls (HC). Forty-seven PD patients were followed up for up to 2 years. Cross-sectional and longitudinal associations between baseline plasma biomarkers and cognitive progression were investigated using linear regression and linear mixed effects models. At baseline, plasma p-tau181 concentration was significantly higher in PD subjects compared with HC (p = 0.026). In PD patients, higher plasma NfL was associated with lower MMSE score at baseline, after adjusting for age, sex and education (p = 0.027). Baseline plasma NfL also predicted MMSE decline over time in the PD group (p = 0.020). No significant association between plasma p-tau181 concentration and baseline or longitudinal cognitive performance was found. While the role of p-tau181 as a diagnostic biomarker for PD and its relationship with cognition need further elucidation, plasma NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD.
ER  -